Evidence map›Paper›PMID 32033937›Full record

SynthesisAnnals of the rheumatic diseases2020

Efficacy of pharmacological treatment in rheumatoid arthritis: a systematic literature research informing the 2019 update of the EULAR recommendations for management of rheumatoid arthritis.

Andreas Kerschbaumer, Alexandre Sepriano, Josef S Smolen, Désirée van der Heijde, Maxime Dougados, Ronald van Vollenhoven, Iain B McInnes, Johannes W J Bijlsma, Gerd R Burmester, Maarten de Wit and 2 more

Open access · bronzeAbstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Annals of the rheumatic diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 131 papers, 13 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
131citing papers in PubMed, 13 pooled it
32.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

131 citing papers in PubMed, 13 syntheses or guidelines pooled it, 284 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Guideline
  11. Pooled it
  12. Pooled it
  13. Pooled it
  14. Trial
  15. Review
  16. Article
  17. Observational
  18. Article
  19. Article
  20. Review

71 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 8 institutions in 8 countries.

Andreas KerschbaumerMedical University of Vienna, Vienna, Austria andreas.kerschbaumer@meduniwien.ac.at.ORCID 0000-0002-6685-8873
Alexandre SeprianoLeiden University Medical Center, Leiden, The Netherlands.ORCID 0000-0003-1954-0229
Josef S SmolenMedical University of Vienna, Vienna, Austria.
Désirée van der HeijdeLeiden University Medical Center, Leiden, The Netherlands.ORCID 0000-0002-5781-158X
Maxime DougadosHospital Cochin, Paris, France.
Ronald van VollenhovenAmsterdam Rheumatology Center, Amsterdam, The Netherlands.
Iain B McInnesUniversity of Glasgow, Glasgow, UK.
Johannes W J BijlsmaUniversity Medical Center Utrecht, Utrecht, The Netherlands.
Gerd R BurmesterCharité - University Medicine Berlin, Berlin, Germany.
Maarten de WitEULAR Standing Committee, Zurich, Switzerland.ORCID 0000-0002-8428-6354
Louise FalzonNorthwell Health, New York, New York, USA.
Robert LandewéAmsterdam Rheumatology Center, Amsterdam, The Netherlands.
Leiden University Medical Center · NLMedical University of Vienna · ATCharité - Universitätsmedizin Berlin · DEEuropean League Against Rheumatism · CHHôpital Cochin · FRNorthwell Health · USUniversity Medical Center Utrecht · NLUniversity of Glasgow · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTo inform the 2019 update of the European League against Rheumatism (EULAR) recommendations for the management of rheumatoid arthritis (RA).

methodsA systematic literature research (SLR) to investigate the efficacy of any disease-modifying antirheumatic drug (DMARD) (conventional synthetic (cs)DMARD, biological (b) and biosimilar DMARD, targeted synthetic (ts)DMARD) or glucocorticoid (GC) therapy in patients with RA was done by searching MEDLINE, Embase and the Cochrane Library for articles published between 2016 and 8 March 2019.

results234 abstracts were selected for detailed assessment, with 136 finally included. They comprised the efficacy of bDMARDs versus placebo or other bDMARDs, efficacy of Janus kinase (JAK) inhibitors (JAKi) across different patient populations and head-to-head of different bDMARDs versus JAKi or other bDMARDs. Switching of bDMARDs to other bDMARDs or tsDMARDs, strategic trials and tapering studies of bDMARDs, csDMARDs and JAKi were assessed. The drugs evaluated included abatacept, adalimumab, ABT-122, baricitinib, certolizumab pegol, SBI-087, CNTO6785, decernotinib, etanercept, filgotinib, golimumab, GCs, GS-9876, guselkumab, hydroxychloroquine, infliximab, leflunomide, mavrilimumab, methotrexate, olokizumab, otilimab, peficitinib, rituximab, sarilumab, salazopyrine, secukinumab, sirukumab, tacrolimus, tocilizumab, tofacitinib, tregalizumab, upadacitinib, ustekinumab and vobarilizumab. The efficacy of many bDMARDs and tsDMARDs was shown. Switching to another tumour necrosis factor inhibitor (TNFi) or non-TNFi bDMARDs after TNFi treatment failure is efficacious. Tapering of DMARDs is possible in patients achieving long-standing stringent clinical remission; in patients with residual disease activity (including patients in LDA) the risk of flares is increased during the tapering. Biosimilars are non-inferior to their reference products.

conclusionThis SLR informed the task force regarding the evidence base of various therapeutic regimen for the development of the update of EULAR's RA management recommendation.

Indexed as

Antirheumatic AgentsArthritis, RheumatoidBiological ProductsBiosimilar PharmaceuticalsDrug SubstitutionDrug Therapy, CombinationGlucocorticoidsHumansJanus Kinase InhibitorsRandomized Controlled Trials as TopicSynthetic DrugsTumor Necrosis Factor-alphaAntirheumatic AgentsBiological ProductsBiosimilar PharmaceuticalsGlucocorticoidsJanus Kinase InhibitorsSynthetic DrugsTumor Necrosis Factor-alphaanti-TNFDMARDs (biologic)DMARDs (synthetic)rheumatoid arthritis

Identifiers

PMID32033937
PMCPMC7286044
OpenAlexW3005067674

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.